Wai Chun Bio-Technology Limited Announces Substantial Reduction in Interim Loss

Key Highlights for Investors

• Substantial Reduction in Net Loss: Wai Chun Bio-Technology Limited expects to post a net loss of not more than HK\$6.0 million for the six months ended 31 December 2025, a significant improvement from the HK\$13.1 million net loss recorded in the same period the previous year.
• Improved Financial Performance: The reduction in loss is primarily attributed to an increase in revenue and a decrease in finance costs during the reporting period.
• Price Sensitive Information: The announcement is made in accordance with Listing Rules and the Inside Information Provisions, indicating its material impact on the company’s valuation and potential to affect share price.
• Ongoing Results Finalization: The interim results for the period are still being finalized. The disclosed figures are based on preliminary and unaudited consolidated management accounts, which have yet to be reviewed by the audit committee.

Details for Shareholders and Potential Investors

Wai Chun Bio-Technology Limited (“the Company”, together with its subsidiaries, “the Group”) has issued a profit alert regarding its financial performance for the six months ended 31 December 2025. Based on the Board’s assessment of the unaudited consolidated management accounts, the Group expects to report a net loss of not more than HK\$6.0 million. This marks a substantial reduction compared to the net loss of approximately HK\$13.1 million for the corresponding period ended 31 December 2024.

The significant improvement in the Group’s financial result is attributed to two key factors:

• Increase in Revenue: The Group achieved higher revenue during the period, which positively impacted the bottom line.
• Decrease in Finance Costs: Reduced finance costs further contributed to the narrowing of losses.

It is important to note that these results are based on unaudited management accounts and are subject to review by the Company’s audit committee. The finalized interim results will be published within the timeframe stipulated under the Hong Kong Listing Rules.

Potential Impact on Share Value and Shareholder Advisory

The announcement represents a material event for Wai Chun Bio-Technology Limited. The substantial reduction in net loss, driven by stronger revenue and lower finance costs, is likely to be viewed positively by the market and could influence the Company’s share price. However, investors should be aware that the details are preliminary and unaudited.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company until the audited interim results are formally released.

Corporate Governance and Board Composition

• Board Chairman and CEO: Mr. Lam Ka Chun
• Independent Non-Executive Directors: Mr. Wong Po Keung, Mr. Wang Ziniu, Ms. Xu Huiling

This announcement was authorized for issue by the Board on 25 February 2026.

Disclaimer: This article is prepared for informational purposes only and does not constitute investment advice. The information is based on preliminary, unaudited data and is subject to change. Investors are advised to consult the official interim results announcement and seek independent financial advice before making any investment decisions.

View WAI CHUN BIOTEC Historical chart here